Revance Therapeutics closes $45M round to advance skin treatments; FDA fast tracks anthrax vaccine;

@FierceBiotech: Pfizer unveils $100M Boston effort to spark R&D innovation. News | Follow @FierceBiotech

@JohnCFierce: Quick shout out to the people who submitted close to 50 Fierce 15 nominations in the first 24 hours. Keep those cards and letters coming! Submission form | Follow @JohnCFierce

> Revance Therapeutics has closed a $45 million financing as the firm advances development of a topical gel form of botulinum toxin type A used to smooth wrinkles in the skin. Release

> The FDA has fast tracked Emergent BioSolutions's Phase I anthrax vaccine, called NuThrax. Emergent release

> Members of North Carolina's Senate Finance committee have once again proposed legislation that would provide funding to biotech start-ups. Critics say the Life Sciences Development Act puts the state in the business of taking on venture capitalists' risk. Report

> Biodefense company PharmAthene plans to sell $6.5 million of its common stock and warrants in a registered direct offering. PharmAthene release

> A novel variant of swine flu has emerged in Asia with a genetic adaptation giving some resistance to Roche's Tamiflu and GlaxoSmithKline's Relenza, the two mainstay drugs used to tackle the disease. Article

Pharma News

@FiercePharma: France suspends Takeda's Actos on cancer data. Item | Follow @FiercePharma

> FTC mulls agency action against pay-for-delay. Article

> UCB to pay $34M for off-label marketing. Story

> Hong Kong yanks GSK drug on phthalate levels. Item

> Germany joins in suspension of Takeda's Actos. Report

Most Popular This Week

> Alzheimer's biomarker market to reach $9B in decade. Item

> Pfizer embarks on a 'first' all-electronic clinical trial. Story

> Roche, Merck to collaborate on cancer diagnostics. Article

> FDA steps in to prevent drug shortages. Report

> Obesity vaccine would suppress hunger hormone. Story

> Cholera molecule helps cocaine addicts kick the habit. Article

> Adult vaccines cut down on healthcare costs. Piece

> Pfizer plots another $1B in cost cuts. Article

> Pfizer unveils $100M Boston effort to spark R&D innovation. Report

And Finally... Orphan diseases are a result of mutations to genes essential to survival, according to research reported in the American Journal of Human Genetics. Report

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.